Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ValiRx raises £500,000 to progess cancer trial

ValiRx has one drug, VAL201, going through phase I/II trials
ValiRx raises £500,000 to progess cancer trial
ValiRx has one drug, VAL201, going through phase I/II trials

ValiRx (LON:VAL) has raised £503,000 gross through a placing at 12p per to fund its drug development pipeline.

ValiRx has one drug, VAL201, going through  phase I/II trials, and has made an application to start a second for another cancer treatment, VAL401.

Satu Vainikka, chief executive said: "We are delighted to be able to raise additional funds through this equity placing in a challenging market.

“These funds will enable the company to progress the clinical trial activity that was recently announced."

PhilW.jpg
Why Invest In ValiRx Plc? Read More Here

Register here to be notified of future VAL Company articles
View full VAL profile

ValiRx Plc Timeline

Related Articles

Astrazeneca1_5704c41deea83.jpg
April 06 2016
Researchers administered Atu027 to patients with pancreatic cancer, one of the hardest strains of the disease to treat.
viagra2.jpg
September 07 2016
It means Futura now has a differentiated product in a market worth US$5bn that , currently dominated by top-selling drugs, such as Viagra and Cialis, that have limitations.
blood_56ceb82789b61.jpg
February 25 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.